Prof Sean Kehoe speaks to ecancer at BGICC 2019 in Cairo about the use of neoadjuvant chemotherapy in advanced ovarian cancer.

He explains that it has been found that women with stage 4 disease have an improved overall survival if they were given neoadjuvant chemotherapy.

Prof Kehoe states that neoadjuvant chemotherapy can also be preferable for patients with a poor performance status.

In these instances if the patient's quality of life improves it can be safer to operate on them.